Zacks Investment Research upgraded shares of Cellectis S.A. (NASDAQ:CLLS) from a sell rating to a hold rating in a research note released on Tuesday, October 24th. The firm currently has $36.00 target price on the biotechnology company’s stock.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
Other research analysts have also recently issued reports about the stock. Jefferies Group LLC restated a buy rating and issued a $47.00 price objective on shares of Cellectis in a research report on Tuesday, September 26th. Nomura decreased their price objective on shares of Cellectis from $49.00 to $43.00 and set a buy rating on the stock in a research report on Wednesday, September 6th. SunTrust Banks, Inc. restated a hold rating and issued a $20.00 price objective on shares of Cellectis in a research report on Friday, October 6th. BidaskClub cut shares of Cellectis from a buy rating to a hold rating in a research report on Tuesday, July 25th. Finally, Wells Fargo & Company reiterated an outperform rating and set a $40.00 price target (up from $33.00) on shares of Cellectis in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $39.50.
Shares of Cellectis (NASDAQ CLLS) opened at $25.06 on Tuesday. Cellectis has a 52-week low of $16.09 and a 52-week high of $35.07.
WARNING: “Cellectis S.A. (CLLS) Upgraded to “Hold” at Zacks Investment Research” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/cellectis-s-a-clls-raised-to-hold-at-zacks-investment-research.html.
A number of hedge funds have recently made changes to their positions in CLLS. Sphera Funds Management LTD. raised its holdings in Cellectis by 27.6% in the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 44,100 shares in the last quarter. Balyasny Asset Management LLC bought a new position in Cellectis in the second quarter worth $719,000. Eqis Capital Management Inc. raised its holdings in Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 2,287 shares in the last quarter. ARK Investment Management LLC raised its holdings in Cellectis by 79.1% in the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares in the last quarter. Finally, Williams Jones & Associates LLC bought a new position in Cellectis in the second quarter worth $244,000. 14.82% of the stock is owned by institutional investors.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.